Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial

Abstract

Background: Heart failure (HF) developing in hypertensive patients may occur with preserved or reduced left ventricular ejection fraction (PEF [>or=50%] or REF [<50%]). In the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), 42 418 high-risk hypertensive patients were randomized to chlorthalidone, amlodipine, lisinopril, or doxazosin, providing an opportunity to compare these treatments with regard to occurrence of hospitalized HFPEF or HFREF.

Methods and results: HF diagnostic criteria were prespecified in the ALLHAT protocol. EF estimated by contrast ventriculography, echocardiography, or radionuclide study was available in 910 of 1367 patients (66.6%) with hospitalized events meeting ALLHAT criteria. Cox regression models adjusted for baseline characteristics were used to examine treatment differences for HF (overall and by PEF and REF). HF case fatality rates were examined. Of those with EF data, 44.4% had HFPEF and 55.6% had HFREF. Chlorthalidone reduced the risk of HFPEF compared with amlodipine, lisinopril, or doxazosin; the hazard ratios were 0.69 (95% confidence interval [CI], 0.53 to 0.91; P=0.009), 0.74 (95% CI, 0.56 to 0.97; P=0.032), and 0.53 (95% CI, 0.38 to 0.73; P<0.001), respectively. Chlorthalidone reduced the risk of HFREF compared with amlodipine or doxazosin; the hazard ratios were 0.74 (95% CI, 0.59 to 0.94; P=0.013) and 0.61 (95% CI, 0.47 to 0.79; P<0.001), respectively. Chlorthalidone was similar to lisinopril with regard to incidence of HFREF (hazard ratio, 1.07; 95% CI, 0.82 to 1.40; P=0.596). After HF onset, death occurred in 29.2% of participants (chlorthalidone/amlodipine/lisinopril) with new-onset HFPEF versus 41.9% in those with HFREF (P<0.001; median follow-up, 1.74 years); and in the chlorthalidone/doxazosin comparison that was terminated early, 20.0% of HFPEF and 26.0% of HFREF patients died (P=0.185; median follow-up, 1.55 years).

Conclusions: In ALLHAT, with adjudicated outcomes, chlorthalidone significantly reduced the occurrence of new-onset hospitalized HFPEF and HFREF compared with amlodipine and doxazosin. Chlorthalidone also reduced the incidence of new-onset HFPEF compared with lisinopril. Among high-risk hypertensive men and women, HFPEF has a better prognosis than HFREF.

Trial registration: ClinicalTrials.gov NCT00000542.

Figure 1.a

Validated Hospitalized HF; Validated HF by Preserved EF, Reduced EF, and No EF Data Categories by Treatment Group (Chlorthalidone/Amlodipine/Lisinopril)

Figure 1.a

Validated Hospitalized HF; Validated HF by Preserved EF, Reduced EF, and No EF Data Categories by Treatment Group (Chlorthalidone/Amlodipine/Lisinopril)

Figure 1b

Validated Hospitalized HF; Validated HF by Preserved EF, Reduced EF, and No EF Data Categories by Treatment Group (Chlorthalidone/Doxazosin)

Figure 1b

Validated Hospitalized HF; Validated HF by Preserved EF, Reduced EF, and No EF Data Categories by Treatment Group (Chlorthalidone/Doxazosin)

Figure 2a

Mortality after occurrence of validated HF with preserved EF (PEF) and reduced EF (REF) in ALLHAT. (Amlodipine/Lisinopril/Chlorthalidone comparison)

Figure 2a

Mortality after occurrence of validated HF with preserved EF (PEF) and reduced EF (REF) in ALLHAT. (Amlodipine/Lisinopril/Chlorthalidone comparison)

Figure 2b

Mortality after occurrence of validated HF with preserved EF (PEF) and reduced EF (REF) in ALLHAT. (Doxazosin/Chlorthalidone comparison)

Figure 2b

Mortality after occurrence of validated HF with preserved EF (PEF) and reduced EF (REF) in ALLHAT. (Doxazosin/Chlorthalidone comparison)